Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase

被引:87
作者
Mai, A
Sbardella, G
Artico, M
Ragno, R
Massa, S
Novellino, E
Greco, G
Lavecchia, A
Musiu, C
La Colla, M
Murgioni, C
La Colla, P
Loddo, R
机构
[1] Univ Roma La Sapienza, Dipartimento Studi Farmaceut, Fdn Cenci Bolognetti, Ist Pasteur, I-00185 Rome, Italy
[2] Univ Roma La Sapienza, Dipartimento Studi Chim & Tecnol Sostanze Biologi, I-00185 Rome, Italy
[3] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy
[4] Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy
[5] Novirio Pharmaceut Inc, Boston, MA USA
[6] Univ Cagliari, Sez Microbiol, Dipartimento Biol Sperimentale, I-09042 Cagliari, Italy
关键词
D O I
10.1021/jm010853h
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
5-Alkyl-2-(alkylthio)-6-(2,6-difluorobenzyl)-3,4-dihydropyrimidin-4(3H)-ones (S-DABOs, 2) have been recently described as a new class of human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) active at nanomolar concentrations (Mai, A. et al. J. Med. Chem. 1999, 42, 619-627). In pursuing our lead optimization efforts, we designed novel conformationally restricted S-DABOs, 3, featuring a methyl at the benzylic carbon (Y = Me) and at the pyrimidine 5-position (R = Me). Conformational analyses and docking simulations suggested that the presence of both methyls would significantly reduce conformational flexibility without compromising, in the R enantiomers, the capability of fitting into the RT non-nucleoside binding pocket. To develop structure-activity relationships, we prepared several congeners of type 3 belonging to the thymine (R = Me) and uracil (R = H) series, featuring various 2-alkylthio side chains (X = Me, i-Pr, n-Bu, i-Bu, s-Bu, c-pentyl, and c-hexyl) and aryl moieties different from the 2,6-difluorophenyl (Ar = phenyl, 2,6-dichlorophenyl, 1-naphthyl). Moreover, alpha -ethyl derivatives (Y = Et) were included in the synthetic project in addition to alpha -methyl derivatives (Y = Me). All of the new compounds were evaluated for their cytotoxicity and anti-HIV-1 activity in MT-4 cells, and some of them were assayed against highly purified recombinant wild-type HIV-1 RT using homopolymeric template primers. The results were expressed as CC50 (cytotoxicity), EC50 (anti-HIV-1 activity), SI (selectivity, given by the CC50/EC50 ratio), and IC50 (RT inhibitory activity) values. In the 2,6-difluorobenzylthymine (R = Me) series, methylation of the benzylic carbon improved anti-HIV-1 and RT inhibitory activities together with selectivity. Compound 3w (Ar = 2,6-F-2-Ph, R = Y = Me, X = c-pentyl) turned out the most potent and selective among the S-DABOs reported to date (CC50 > 200 muM, EC50 = 6 nM, IC50 = 5 nM, and SI > 33 333). Assays performed on the pure enantiomer (+)-3w, much more active than (-)-3w, yielded the following results: CC50 > 200 muM, EC50 = 2 nM, IC50 = 8 nM, and SI > 100 000, under conditions wherein MKC-442 was less active and selective (CC50 > 200 muM, EC50 = 30 nM, IC50 = 40 nM, SI > 6666). The 2,6-difluorophenylethylthymines (R = Me) were generally endowed with higher potency compared with the uracil counterparts (R = H). In the 2,6-difluorophenyl series the best and the least performant 2-alkylthio side chains were the 2-c-pentylthio and the 2-methylthio, respectively. When the methyl at the benzylic carbon was replaced by an ethyl, activity was retained or decreased slightly, thus suggesting that the dimensions of the cavity within the RT hosting this substituent would not be compatible with groups larger than ethyl. Aryl moieties different from the 2,6-difluorophenyl (phenyl, 1-naphthyl, 2,6-dichlorophenyl) were generally detrimental to activity, consistent with a favorable electronic effect exerted by the 2,6-fluorines on a putative charge-transfer interaction between the aromatic moieties of the inhibitor and Tyr188.
引用
收藏
页码:2544 / 2554
页数:11
相关论文
共 49 条
  • [1] CONFORMATIONAL-ANALYSIS .130. MM2 - HYDROCARBON FORCE-FIELD UTILIZING V1 AND V2 TORSIONAL TERMS
    ALLINGER, NL
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1977, 99 (25) : 8127 - 8134
  • [2] 3,4-DIHYDRO-2-ALKOXY-6-BENZYL-4-OXOPYRIMIDINES (DABOS) - A NEW CLASS OF SPECIFIC INHIBITORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    ARTICO, M
    MASSA, S
    MAI, A
    MARONGIU, ME
    PIRAS, G
    TRAMONTANO, E
    LACOLLA, P
    [J]. ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1993, 4 (06) : 361 - 368
  • [3] HIGHLY SPECIFIC-INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 BY A NOVEL 6-SUBSTITUTED ACYCLOURIDINE DERIVATIVE
    BABA, M
    TANAKA, H
    DECLERCQ, E
    PAUWELS, R
    BALZARINI, J
    SCHOLS, D
    NAKASHIMA, H
    PERNO, CF
    WALKER, RT
    MIYASAKA, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 165 (03) : 1375 - 1381
  • [4] MOLECULAR-DYNAMICS WITH COUPLING TO AN EXTERNAL BATH
    BERENDSEN, HJC
    POSTMA, JPM
    VANGUNSTEREN, WF
    DINOLA, A
    HAAK, JR
    [J]. JOURNAL OF CHEMICAL PHYSICS, 1984, 81 (08) : 3684 - 3690
  • [5] PROTEIN DATA BANK - COMPUTER-BASED ARCHIVAL FILE FOR MACROMOLECULAR STRUCTURES
    BERNSTEIN, FC
    KOETZLE, TF
    WILLIAMS, GJB
    MEYER, EF
    BRICE, MD
    RODGERS, JR
    KENNARD, O
    SHIMANOUCHI, T
    TASUMI, M
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1977, 112 (03) : 535 - 542
  • [6] Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors .2. Synthesis and further structure-activity relationship studies of PETT analogs
    Cantrell, AS
    Engelhardt, P
    Hogberg, M
    Jaskunas, SR
    Johansson, NG
    Jordan, CL
    Kangasmetsa, J
    Kinnick, MD
    Lind, P
    Morin, JM
    Muesing, MA
    Noreen, R
    Oberg, B
    Pranc, P
    Sahlberg, C
    Ternansky, RJ
    Vasileff, RT
    Vrang, L
    West, SJ
    Zhang, H
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (21) : 4261 - 4274
  • [7] VALIDATION OF THE GENERAL-PURPOSE TRIPOS 5.2 FORCE-FIELD
    CLARK, M
    CRAMER, RD
    VANOPDENBOSCH, N
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 1989, 10 (08) : 982 - 1012
  • [8] A 2ND GENERATION FORCE-FIELD FOR THE SIMULATION OF PROTEINS, NUCLEIC-ACIDS, AND ORGANIC-MOLECULES
    CORNELL, WD
    CIEPLAK, P
    BAYLY, CI
    GOULD, IR
    MERZ, KM
    FERGUSON, DM
    SPELLMEYER, DC
    FOX, T
    CALDWELL, JW
    KOLLMAN, PA
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1995, 117 (19) : 5179 - 5197
  • [9] Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant
    Das, K
    Ding, JP
    Hsiou, Y
    Clark, AD
    Moereels, H
    Koymans, L
    Andries, K
    Pauwels, R
    Janssen, PAJ
    Boyer, PL
    Clark, P
    Smith, RH
    Smith, MBK
    Michejda, CJ
    Hughes, SH
    Arnold, E
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1996, 264 (05) : 1085 - 1100
  • [10] The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
    De Clercq, E
    [J]. ANTIVIRAL RESEARCH, 1998, 38 (03) : 153 - 179